Antigen-specific T cell activation requires two independent signalling events, one mediated through T cell receptor engagement by the antigen-presenting cell-expressed peptide/ class II major histocompatibility complex, and the second through the cognate interactions of costimulatory molecules expressed on the T cell and antigen-presenting cell. There is evidence from in vitro and in vivo experimental systems suggesting that the CD28/B7 costimulatory pathway is crucial for induction of maximal T cell proliferation and T helper-B cell collaboration for IgG production. This pathway can be blocked by CTLA-4-Ig, a soluble form of CTLA-4 which binds with high avidity to the CD28 ligands, B7-1 and B7-2. Here, we show that CTLA-4-Ig treatment prevents clinical and histological manifestations of disease in a collagen-induced arthritis model of rheumatoid arthritis in the diabetes resistant BB/Wor rat, when therapy is initiated before immunization with bovine type II collagen (BUC). Anti-BUC antibody titers are reduced in CTLA-4-Igtreated rats compared to diseased control animals. Histologically, joints from CTLA-4-Ig-treated animals show no histological abnormalities, in contrast to control antibodytreated animals, which show complete erosion of the articular cartilage and bone. Despite the efficacy of CTLA-4-Ig in preventing clinical and histological signs of arthritis and reducing antibody responses to BIIC, delayed type hypersensitivity responses to collagen 18 d or more after CTLA-4-Ig treatment ends are similar in CTLA-4-Ig-treated and untreated rats, suggesting that the prolonged disease suppression observed does not result from induction of T cell anergy. (J. Clin. Invest. 1995. 96:987-993.)
Introduction
Optimal activation of antigen-specific T cells requires the induction of a nonspecific costimulatory signalling pathway, in addition to the primary antigen-specific signal delivered by T cell receptor engagement (1, 2) . One such costimulatory accessory molecule is the T cell surface antigen, CD28, whose interaction with its antigen-presenting cell-expressed ligands B7-1 and B7-2 during TCR engagement has been shown to be crucial for maximal T cell signalling (3) . B7 ligand binding to CD28 costimulates T cell proliferation and IL-2 transcription (4-6), and monoclonal antibodies directed against both B7 and CD28 specifically block T helper (Th)-mediated Ig production by B cells in vitro (7) . These observations demonstrate the importance of the CD28/B7 costimulus to the functional collaboration between Th and B cells. The CD28/B7 costimulatory pathway can also be blocked with a chimeric Ig fusion protein of CTLA-4, a CD28 homologue which binds B7-1 and B7-2 with high avidity (8, 9) . CTLA-4-Ig binding to B7 has been shown to potently inhibit both Th proliferation and Ig secretion by B cells in vitro (8) .
Antigen stimulation through the TCR in the absence of costimulation can lead to antigen-specific hyporesponsiveness or clonal T cell anergy in vitro (3) . For this reason, there has been much interest recently in identifying therapeutic approaches aimed at blocking costimulation, especially in the areas of tissue transplantation and autoimmunity. Because there is no humanrodent species barrier to CTLA-4/B7 interaction, the effects of CD28/B7 pathway blockade using human CTLA-4-Ig constructs have been studied in a variety of rodent-based disease models. In recent in vivo experiments, CTLA-4-Ig treatment has been shown to suppress primary, and to a lesser extent, secondary antibody responses to sheep erythrocytes and keyhole limpet hemocyanin immunogens (10) , block xenogeneic pancreatic islet rejection in mice and induce long-term, donor-specific tolerance to the graft ( 11) , increase cardiac allograft survival in rats ( 12) , and block autoantibody production, and prolong survival of mice affected by systemic lupus erythematosis (13) . The induction of anergy, rather than prolonged immunosuppression, by CTLA-4-Ig in these systems is variable, and may depend upon the potency of the immunogen, the use of species-matched CTLA-4-Ig, or a variable dependence of certain T cell populations on B7 costimulation.
The diabetes-resistant (DR) BB/Wor rat is a subline of the diabetes-prone BB rat which develops severe, aggressive arthritis upon immunization with heterologous native type II collagen (14) . Arthritis develops bilaterally with 100% incidence in the hindpaws, with clinical signs beginning at day + 10 after a single collagen injection. Significantly, the DR BB/Wor rat has a major histocompatibility complex (MHC) genetic background relevant to that predisposing to human RA; it shares with RA-susceptible humans a homologous MHC class IT-encoded arthritis susceptibility epitope (14) . Progression of the disease is associated with infiltration into the periarticular space of mononuclear and multinucleated inflammatory cells and re-sorption of articular cartilage and bone (14) . Histologically, DR BB/Wor collagen-induced arthritis resembles human rheumatoid arthritis: multinucleated giant cells, pallisading cells, and pregranulomatous nodules are seen in sections of severely affected joints (Barney Knoerzer, D., B. D. Schwartz, and L. J. Mengle-Gaw, unpublished observations). Antibody mechanisms have been implicated in the pathogenesis of arthritis in this model (14) .
In this report, we show that administration of soluble CTLA-4-Ig prevents development of clinical manifestations of collagen-induced arthritis in the DR BB/Wor rat during observation periods up to 62 d. These results demonstrate for the first time that blockade of the CD28/B7 costimulation pathway prevents disease in an in vivo arthritis model.
Methods
Animals. DR 3-digit deformity; 4-ankle deformity (full ankylosis). All clinical score measurements were performed without knowledge of the treatment regimen the rats received.
Determination of serum anticollagen antibody titers. Sera for determination of IgG anti-BIIC antibody titers were obtained by retroorbital bleeding on various days after collagen immunization or from naive age-matched animals. Serum samples were stored at -20'C and were heat inactivated before testing by ELISA. Briefly, microtiter plates (Nunc Immuno Maxisorp, Kirkegard and Perry Laboratories, Inc., Gaithersburg, MD) were coated with 0.1 ml of 0.01 mg/ml native BUC in phosphate buffer at 40C overnight. After washing, the wells were blocked with ELISA buffer (1% BSA in PBS). Serum samples, diluted 1:500, 1:2,500, and 1:5,000 in ELISA buffer, were added to wells and incubated 2 h at 250C. BIIC-bound serum IgG were detected by a horseradish peroxidase-conjugated goat anti-rat IgG (Accurate Chemical and Scientific Corp., Westbury, NY), and plates were developed using ABTS peroxidase substrate (Kirkegard and Perry Laboratories, Inc.) and read at 405 nm on an automated microplate reader (model 3550; Bio-Rad Laboratories, Richmond, CA). Results are expressed as OD units (experimental wells minus baseline OD). A serum with known high levels of anti-BIIC antibodies was used to generate a highly reproducible standard curve as part of each experiment.
Histology. Relevant paws taken from animals killed at the end of the study were skinned and placed in 10% buffered phosphate formalin (Fisher Scientific Co., Pittsburgh, PA) for > 1 wk before being subjected to acid decalcification (19) . Decalcified paws were embedded in paraffin, longitudinally sectioned through the center of the tibia-tarsal joint (Histo Techniques, Powell, OH), and stained with hematoxylin and eosin (19 ankylosis by day + 16 (Fig. 1 A) Fig. 1 B. Anti-BUC antibody levels of UPC-10-treated control animals rose rapidly during the first 19 d, in parallel with the development of arthritis in these animals, then persisted at high levels during the remainder of the observation period. Although antibody levels in CTLA4-Ig-treated rats also rose over time, the antibodies consistently appeared later than in the control-treated rats and the levels were significantly lower at each time point analyzed than in the control-treated rats (P < 0.05). Sera from naive age-matched rats have a mean OD of 0.025 at day +41 (Fig. 1 B) . Anti-BUC antibody levels were also measured at three serum dilutions in day + Histological analysis of CTLA-4-Ig-treated joints. Hindpaw joints from immunized CTLA-4-Ig-treated rats were examined at day +47 by light microscopy and compared to joints from normal, unimmunized rats, and immunized rats (day +47) receiving UPC-10 control antibody treatment. These sections are compared in Fig. 2 . Compared to the normal joint architecture seen in unimmunized animals (Fig. 2 A) , the joints from BUC-immunized, UPC-10 control-treated rats show significant pannus formation and complete erosion of cartilage and bone at day +47 (Fig. 2 B) . By contrast, joints from BIUC-immunized, CTLA4-Ig-treated rats show no histological abnormalities at day +47 (Fig. 2 C) .
Cellular response to bovine type II collagen in CTLA-4-Igtreated rats. Skin delayed type hypersensitivity responses to BUC were measured in CTLA-4-Ig-treated and control animals ( Table I ). 4 rats/treatment group were assessed at day +22 and +28 after collagen immunization. The same rats were used for DTH measurement at both day +22 and +28, and were a subset of those whose clinical scores and anti-BUC antibody titers are shown in Fig. 1 . At day +22, the mean DTH score for the CTLA-4-Ig-treated animals was 0.9, with three of the four animals showing no DTH response; this compares with mean DTH scores of 5.2 and 4.7 for the UPC-10-treated and saline-treated control groups, respectively, and represents a significant difference in the ability of CTLA-4-Ig vs UPC-10-treated rats to generate DTH responses to collagen at day +22 (P < 0.005). By contrast, the DTH responses at day +28 of t MeantSD calculated using all tested animals in each treatment group.
that the positive DTH responses at day +28 were due to antigen priming with collagen during DTH testing at day +22, additional experiments were done: In two separate experiments, four of four and six of six CTLA-4-Ig-treated rats without arthritis had positive DTH responses to collagen on first testing at day +29 or +36, respectively (data not shown). No CTLA-4-Igtreated rats developed arthritis following DTH testing. Collagen rechallenge. In pilot studies, we observed that a CTLA-4-Ig-treated rat without arthritis at day +33 after initial collagen immunization developed robust arthritis after rechallenge with collagen and IFA at day +33. We subsequently conducted a collagen rechallenge experiment with and without the administration of CTLA-4-Ig during the rechallenge, using the six CTLA-4-Ig-treated rats shown in Fig. 1 A. At day +50 after the initial collagen immunization and CTLA-4-Ig treatment, each of the CTLA-4-Ig-treated rats had a clinical score of zero. The CTLA-4-Ig-treated rats were divided into two treatment groups in association with collagen rechallenge (BUC 100 ,ug in WFA) at day +50: two rats received no additional CTLA-4-Ig treatment, and four rats received seven doses of CTLA-4-Ig during days +47 to +56 (Fig. 3) . The untreated 16 Figure rats developed arthritis after collagen rechallenge, with clinical scores of eight and six, respectively, at day +75 and maximum scores of nine and eight during the observation period. The kinetics of arthritis development in these rats were similar to those seen in untreated rats in response to primary collagen immunization (Fig. 1 A) . Three of the rats treated with CTLA-4-Ig during the rechallenge did not develop arthritis (clinical scores, zero) through the observation period to day +105. One of the CTLA-4-Ig-treated rats developed arthritis by day +61 (clinical score, three), with a maximum score of six at day + 105. Anti-BUC antibody levels remained comparably elevated in the CTLA-4-Ig-treated rat that developed arthritis and in those without arthritis (data not shown). At day + 105, histopathology of joints from rats that did and did not develop arthritis after collagen rechallenge was compared (Fig. 4) . A hindpaw tibia-tarsal joint from the CTLA4-Ig-treated rat that developed moderate arthritis following rechallenge shows significant pannus formation and erosion of cartilage and bone (Fig. 4 A) . By comparison, joints from rechallenged CTLA-4-Ig-treated rats without arthritis showed no histological abnormalities (Fig.  4 B Although data from other studies indicate a role for anti-BIIC antibodies in the pathogenesis of collagen-induced arthritis in the BB rat, CTLA-4-Ig-treated rats produced anti-BIIC antibodies but did not develop arthritis. However, the anti-BIIC antibody levels in CTLA-4-Ig-treated rats were consistently lower than in control-treated rats. In other model systems, inhibition or absence of CD28 costimulation has been shown to decrease Th-mediated antibody responses (10, 24) and T cell proliferation (25) . The prevention of arthritis by CTLA-4-Ig in our studies suggests that T cell proliferation may be more susceptible to inhibition by CTLA-4-Ig than antibody production and that both T cell proliferation and anti-BIIC antibodies are required to produce arthritis.
In spite of the absence of arthritis, CTLA-4-Ig-treated rats display positive delayed type hypersensitivity responses to bovine HC at day +28, comparable to those observed in immunized, control-treated animals. This result clearly indicates that CTLA-4-Ig treatment has not caused antigen-specific T cell hyporesponsiveness, or anergy, in these rats. The inability of CTLA-4-Ig-treated rats to generate BUC-specific DTH responses early in the experimental course may reflect the presence of residual serum CTLA-4-Ig, a hypothesis supported by results of in vivo studies showing slow serum clearance rates for CTLA-4-Ig (10, 26) . Prolonged immunosuppression without anergy has been reported in other in vivo experimental systems, where CTLA-4-Ig has been used to block T-dependent antibody responses, and has been suggested to result from variable dependence of certain T cell populations on B7 costimulation (10) . Our data indicate that CTLA-4-Ig treatment prevents collageninduced arthritis and protects rats rechallenged with collagen from developing arthritis, presumably by blocking activation of arthritis-inducing T cells, but does not prevent generation of cells that could participate in a DTH response to collagen. The immunoregulatory network that prevents the in vivo activation of these cells remains to be defined.
The data reported herein suggest that blockade of the CD28/ B7 costimulatory pathway may be efficacious for the treatment of human rheumatoid arthritis.
